wisp semaglutide launches weight care vertical for women with hormonal imbalances Semaglutide Weight-Loss Program Las Vegas

Our 2025 study in JMIR Formative Research examined 12-month outcomes for participants using semaglutide with behavioural support and found 1 : 19.1% average weight loss at 12 months for active subscribers 77.7% achieved at least 10% weight loss 61.5% achieved at least 15% weight loss 69% reported no side effects by month 12 These are completer results (people who stayed on the programme for 12 months), not intent-to-treat

What makes this approval especially interesting is convenience

Purification of a recombinant protein with cellulose- binding module 3 as the affinity tag

adults showed 13% have used a GLP-1 medication

USA 103 , 63686373 (2006)

A reader who believes evidence is being hidden looks for the smoking gun